Source: MarketScreener

Lee's Pharm: Unicycive Therapeutics : Announces Exclusive License and Development Agreement with Lee's Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets - Form 8-K

(marketscreener.com) Unicycive Announces Exclusive License and Development Agreement with Lee's Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets Expands and accelerates Renazorb opportunity in important markets for patients with hyperphosphatemia through local partner with deep domain expertise ...https://www.marketscreener.com/quote/stock/UNICYCIVE-THERAPEUTICS-I-123776316/news/Unicycive-Therapeutics-Announces-Exclusive-License-and-Development-Agreement-with-Lee-s-Pharmaceut-41014791/?utm_medium=RSS&utm_content=20220718

Read full article »
Est. Annual Revenue
$5.0-25M
Agree?
Est. Employees
1-25
Agree?
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100



Lee's Pharm is a Private company. Lee's Pharm generates $1M in revenue per employee Lee's Pharm has 2 followers on Owler.